Outstanding Benefits for Patients

DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES

  • Tumors have latent vulnerabilities that can be identified through ETA.
  • Agnostic to stage, grade, anatomy or morphology.
  • Integrational multi-analyte interrogation of tumor interactome and tumor function.
  • Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.

Who will Benefit

First-line therapy has failed.
Risk of therapy failure is high.
Cancer has relapsed.
For newly diagnosed patients to explore best therapy options.
Cancer is high-grade / metastatic.

See the Results for Yourself

Patients who have not benefited from chemo-therapy require ultra-personalized treatment. We specialize in providing guidance for difficult cases by using highly sophisticated molecular analysis technology. We have a clinically proven track record of extremely high success.

Presentation

Conventional versus Modern

Why Exacta

Exacta® is an intensive and in depth tumor gene expression analysis. It analyses 100s of millions of data points at the molecular level to reveal all possible targets for precision drugs. Exacta® is one of the most powerful tumor investigation and is an extreme analytical tool that reveals the driven mutations and pathways driving a personʼs cancer. Exacta is best molecular analysis for difficult cancers.

Features

Determines deepest genetic facets of an individual patientʼs cancer.
Accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome.
Reaches the depths of cancerʼs mechanism through 100ʼs of millions of data points.
Reveals mutations and pathways that are propelling a particular cancer in an individual.
Enables a highly sophisticated treatment strategy beyond conventional perspective.

Clinically Validated (Publications)

The validation data for Exacta / The resilient protocol has been extensively published in leading peer reviewed journals.

Publications

CONTACT US

I have read and understood the terms of use and the privacy policy and I agree.



7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
3
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
Go to Index
Go to Index
Go to Index
Go to Index
Go to Index